Baselake reports 5.2% stake in Generation Bio
Generation Bio Co. received a new ownership disclosure from Baselake-affiliated investors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Generation Bio Co. received a new ownership disclosure from Baselake-affiliated investors. Baselake Partners, LP, Baselake Management, LLC, and individual investor David Paolella report beneficial ownership of 350,000 shares of Generation Bio common stock, representing 5.2% of the outstanding shares.
The shares are held by Baselake Partners, LP, with Baselake Management, LLC as investment manager and Paolella as managing member, giving them shared voting and dispositive power over the position. The percentage is based on 6,737,899 shares outstanding as of October 31, 2025, and the filers state the shares are not held to change or influence control of the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Generation Bio Co. (GBIO) does Baselake report?
Who are the reporting persons in the Generation Bio (GBIO) Schedule 13G?
How did Baselake calculate its 5.2% ownership of Generation Bio (GBIO)?
Is Baselake’s Generation Bio (GBIO) position intended to influence control of the company?
What ownership disclaimer do Baselake and David Paolella make in the GBIO filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.